5-Amino-1MQ

5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor. NNMT is an enzyme highly expressed in white adipose tissue (fat cells) that consumes SAM (S-adenosylmethionine) and NAD+ precursors, directing them toward methylation reactions. By inhibiting NNMT, 5-Amino-1MQ prevents this NAD+ precursor consumption, raising intracellular NAD+ levels specifically in adipose tissue. The elevated NAD+ activates SIRT1, a sirtuin deacetylase that promotes fat cell lipolysis, reduces fat cell size, and enhances metabolic rate. This mechanism is entirely distinct from GLP-1 agonism (appetite) or AOD-9604 (GH fragment lipolysis) — 5-Amino-1MQ works at the metabolic programming level of fat cells themselves. It is taken orally, making it uniquely accessible for users who cannot or prefer not to inject.

Discovered at the Sanford Burnham Prebys Medical Discovery Institute. A 2021 study in Nature Communications demonstrated that 5-Amino-1MQ treatment of obese mice produced significant fat mass reduction, improved glucose tolerance, and increased metabolic rate without changes in food intake — suggesting a purely metabolic rather than appetite-based mechanism. A separate study showed it reduced fat cell size by 50% in human adipose tissue culture models. Human clinical trials have not yet been published. Growing rapidly in the fat loss community as the only oral compound in the category with a mechanistically distinct pathway. Frequently stacked with GLP-1 protocols to address the metabolic programming layer alongside appetite suppression.

8–12 weeks